Taurine Eye Drops May Prevent the Progression of Cataract

University Of Anbar

Status and phase

Active, not recruiting

Phase 2

Phase 1

Conditions

Cataract

Treatments

Drug: Taurine

Study type

Interventional

Funder types

Other

Identifiers

NCT06639711

UOANBAR-170

Details and patient eligibility

About

The aim of the current intervention study is to determine the effectiveness of taurine containing eye drops (available under brand name VIZILOTON) to prevent the progression of grade I and II senile cataract.

This study could answer:

Dose continuous use of taurine-containing eye drops could prevent further deterioration of vision in mild cases of cataract?
The acceptance/ compliance of participants to taurine-containing eye drops.
Could long-term use of taurine-containing eye drops cause adverse effect(s)?

Participants will:

Take taurine-containing eye drops (VIZILOTON eye drops) 4 times a day for one year.
Visit eye clinic every 3 months for assessment and visual examination.
Keep notes for their symptoms and their adherence to treatment.

Enrollment

50 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The presence of grade I or II senile cataract on one or two eyes.

Exclusion criteria

clinical signs of glaucoma
history of amblyopia, eye surgery, argon or YAG laser eye treatment, or major eye trauma
history of iritis, retinal crystalline deposits, or optic nerve disease
visually significant fundus pathology